Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lipocine (LPCN) EBT Margin (2018 - 2025)

Historic EBT Margin for Lipocine (LPCN) over the last 8 years, with Q3 2025 value amounting to 2781.46%.

  • Lipocine's EBT Margin changed N/A to 2781.46% in Q3 2025 from the same period last year, while for Sep 2025 it was 126.66%, marking a year-over-year decrease of 725300.0%. This contributed to the annual value of 0.08% for FY2024, which is 5736500.0% up from last year.
  • As of Q3 2025, Lipocine's EBT Margin stood at 2781.46%.
  • In the past 5 years, Lipocine's EBT Margin registered a high of 4882.9% during Q1 2021, and its lowest value of 7037.7% during Q1 2023.
  • Moreover, its 5-year median value for EBT Margin was 354.13% (2025), whereas its average is 1216.4%.
  • In the last 5 years, Lipocine's EBT Margin skyrocketed by 70838300bps in 2024 and then plummeted by -20327000bps in 2025.
  • Quarter analysis of 5 years shows Lipocine's EBT Margin stood at 78.48% in 2021, then plummeted by -771bps to 526.36% in 2022, then surged by 301bps to 1055.42% in 2023, then crashed by -95bps to 51.04% in 2024, then plummeted by -5549bps to 2781.46% in 2025.
  • Its EBT Margin was 2781.46% in Q3 2025, compared to 354.13% in Q2 2025 and 1986.57% in Q1 2025.